Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 25, 2024VaccineOpen Access

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMathieu Le GarsJSJerald SadoffVCVicky Cárdenas

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gars et al. (2024) studied this question.

synapsesocial.com/papers/68e635deb6db6435875c7a9dhttps://doi.org/10.1016/j.vaccine.2024.03.079
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis2021 · 450 citations
  2. 2Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa2022 · 1,917 citations
  3. 3Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S2022 · 252 citations
  4. 4Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming2022 · 128 citations
  5. 5Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study2022 · 85 citations